Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 288 | 4 | 294 | +10 |
| Shares | 84.4M | 1.81M | 87.2M | +4.59M (+5.6%) |
| Value | $5.34B | $114.5M | $4.54B | −$684.0M (−13.1%) |
4 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (42)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (32)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
Not filed for Q3 2023 yet (4)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 1,671,846 | $105.9M |
| Tekla Capital Management LLC | 131,435 | $8.32M |
| PFS Investments Inc. | 3,490 | $221.0K |
| Kistler-Tiffany Companies, LLC | 1,000 | $63.3K |